Loading
A phase 1/2 trial of JSKN016, Capecitabine, Eribulin and Pembrolizumab in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, now recruiting.
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer. ClinicalTrials.gov record last updated 2025-09-17: recruiting. Enrollment is planned at 180 participants. Primary completion is estimated at 2027-06-30. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: JSKN016, Capecitabine, Paclitaxel (albumin bound), Eribulin, Pembrolizumab. Registered primary measures: Objetctive Response Rate (ORR).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Eribulin, TROP2, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Alphamab Oncology, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares TROP2, Capecitabine, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Eribulin, Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Eribulin, Capecitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/